Moody Aldrich Partners’s Praxis Precision Medicines PRAX Stock Holding History

Moody Aldrich Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.38M	Sell	19,066 -2,622	-12%	-$830K	1.15%	23
2026 Q1	$6.99M	Sell	21,688 -20,043	-48%	-$6.2M	1.26%	10
2025 Q4	$12.3M	Buy	+41,731	New	+$7.77M	2.3%	1
2025 Q2	–	Sell	-30,221	Closed	-$1.14M	–	196
2025 Q1	$1.14M	Sell	30,221 -456	-1%	-$28.5K	0.24%	108
2024 Q4	$2.36M	Sell	30,677 -928	-3%	-$67.1K	0.44%	90
2024 Q3	$1.82M	Buy	31,605 +7,224	+30%	+$390K	0.33%	105
2024 Q2	$1.01M	Buy	+24,381	New	+$1.15M	0.2%	115

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Moody Aldrich Partners's PRAX Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Praxis Precision Medicines (PRAX) stake by 12% in Q2 2026, selling an estimated $830K and leaving 19,066 shares worth $6.38M. The position accounts for 1.15% of the portfolio, ranked #23.

Moody Aldrich Partners first reported a position in PRAX in Q2 2024 and has held it in 7 quarters since. The position peaked at $12.3M in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Moody Aldrich Partners held 19,066 shares of Praxis Precision Medicines worth $6.38M as of Q2 2026.
Moody Aldrich Partners sold 2,622 Praxis Precision Medicines shares in Q2 2026, an estimated $830K.
Praxis Precision Medicines made up 1.15% of Moody Aldrich Partners's portfolio in Q2 2026, its #23 holding.
Moody Aldrich Partners first reported a position in Praxis Precision Medicines in Q2 2024 and has held it in 7 quarters since.
Moody Aldrich Partners's Praxis Precision Medicines position peaked at $12.3M in Q4 2025.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.